GlassScriptPhysician profile
Maciel Cruz
NPI 1699320010
$1,297.01
in general payments reported to CMS, 2019-2025
10 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.67 · 2020: $56.04 · 2021: $136 · 2022: $20.54 · 2023: $301 · 2024: $528 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $998.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $998.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $484.11 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Bausch & Lomb Americas INC. | $278.11 | 2023-2025 | Xiidra, Miebo |
| Sun Pharmaceutical Industries INC. | $153.65 | 2024-2025 | |
| Allergan, INC. | $135.71 | 2021 | |
| Carl Zeiss Meditec, INC. | $103.91 | 2019-2020 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Harrow Eye, LLC | $34.75 | 2025 | Vevye |
| Horizon Therapeutics Plc | $24.89 | 2023 | Tepezza |
| Astellas Pharma US INC | $22.54 | 2025 | Izervay |
| Coopervision INC. | $20.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maciel Cruz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.